Hualan Biological Vaccine Inc. Class A

Hualan Biological Vaccine Inc. Class A

SSZSE:301207
14.05
CNY
-0.25
(-1.75%)
0.08EPS
259.22P/E
12.09BMarket Cap
Mar 29Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.53
1.49
1.94
4.49
3.39
3.09
4.01
1.89
2.02
1.17
Basic EPS, GAAP
-0.14
0.5
0.69
1.71
1.15
0.88
1.43
0.34
0.31
0.08
Free Cash Flow per Basic Share
-0.01
0.06
0.24
0.3
-0.12
0.33
1.37
0.7
0.58
- -
Dividend per Share
0.19
- -
- -
0.01
0.02
0.15
0.21
0.56
0.85
0.69
Book Value per Share
1.14
1.64
2.34
4.05
5.2
9.16
10.44
10
9.49
8.59
Tangible Book Value per Share
1.1
1.58
2.27
3.97
5.12
9.09
10.36
9.92
9.41
8.51
Basic Weighted Avg Shares
540
540
540
540
540
590
601
598
595
595
Sales/Revenue/Turnover
285
803
1,049
2,426
1,830
1,826
2,410
1,128
1,203
697
Operating Margin (%)
-25.14
38.5
45.45
46.94
44.35
38.05
41.96
15.28
15.6
3.85
Depreciation Expense
34
27
34
41
69
135
140
140
141
- -
Net Income, GAAP
-77
270
375
925
621
520
860
206
183
46
Effective Tax Rate (%)
- -
10.35
13.14
13.89
12.01
11.85
14.59
4.21
2.59
- -
Profit Margin (%)
-26.98
33.65
35.78
38.12
33.94
28.46
35.68
18.22
15.21
6.62
Working Capital
321
507
731
1,010
857
2,656
3,541
3,512
3,266
3,948
LT Debt
- -
- -
- -
2
1
- -
- -
- -
- -
- -
Total Equity
617
887
1,262
2,187
2,808
5,497
6,263
6,013
5,704
5,164
Return on Invested Capital (%)
- -
46.99
51.49
63.34
23.66
11.77
14.25
3.27
3.17
- -
Return on Capital (%)
- -
35.93
34.93
51.03
22.2
11.62
14
3.28
3.09
- -
Return on Common Equity (%)
- -
35.93
34.93
53.63
24.86
12.51
14.63
3.35
3.12
0.83

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
601
601
601
Market Capitalization
11,570
9,791
12,087

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,459
4,395
5,034
Cash, Cash Equivalents & STI
2,564
2,151
2,094
Accounts Receivable, Net
1,187
900
912
Inventories
263
367
372
Total Current Liabilities
1,076
993
1,086
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.79%
-5.14%
Free Cash Flow
- -
-56.02%
-16.57%
Net Income, GAAP
- -
-14.16%
-10.99%
Sales/Revenue/Turnover
- -
-7.88%
6.62%
Total Cash Common Dividend
- -
209.2%
51.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34
1
922
170
1,128
2025
24
36
- -
397
1,203
2026
27
18
257
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
-0.02
0.4
-0.1
0.34
2025
0.06
-0.02
- -
0.09
0.31
2026
0.06
- -
-0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.56
- -
- -
0.56
2025
0.05
0.05
- -
0.62
0.85
2026
- -
- -
0.07
- -
- -

Company Description

CEO
Wen Jue An
Full Time Employees
708
Sector
Health technology
Industry
Biotechnology
Address
Jia No. 1-1, Hualan Avenue Xinxiang HN China 453003
IPO Date
Feb 18, 2022
Business
Hualan Biological Bacterin Inc. (301207.SZ) develops, manufactures and markets human vaccines with a focus on influenza, meningococcal and hepatitis B immunizations. The company offers Influenza Vaccine (Split Virion), Inactivated (Adult and Children); Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Adult, in vial and prefilled syringe formats); Group A and C Meningococcal Polysaccharide Vaccine; Group ACYW135 Meningococcal Polysaccharide Vaccine; and Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10µg in 0.5mL vial and prefilled syringe formats). Founded in 2005 and headquartered at No. 1-1 Hualan Avenue, Xinxiang City, Henan Province, China, it operates primarily in the biopharmaceutical sector targeting domestic and international markets including Asia, Europe, the Americas and Ukraine. A holding subsidiary of Hualan Biological Engineering Inc., it pioneered the world's first marketed Influenza A (H1N1) Vaccine in 2009 and became the first Chinese influenza vaccine producer to receive WHO prequalification. Recent developments include a strategic partnership with Russia's Pharmasyntez announced in October 2025 for joint drug development, technology transfer and localized production of therapeutic monoclonal antibodies at Pharmasyntez facilities.